Korea Institute of Science and Technology has described nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators acting as nitric oxide (NO) production inhibitors and antioxidants reported to be useful for the treatment of acute respiratory distress syndrome, chronic kidney disease, chronic obstructive pulmonary disease, kidney fibrosis, nonalcoholic fatty liver disease, viral hepatitis, Parkinson’s disease and Alzheimer’s disease.

University of Minnesota has divulged nonstructural protein 14 (NSP14) (SARS-CoV-2) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.

Researchers at Centre Hospitalier de Université de Montréal and University of Pennsylvania have identified compounds reported to be useful for the treatment of HIV-1 infection.

Xiamen University has synthesized oligopeptides targeting β2-microglobulin (B2M) reported to be useful for the treatment of cancer and Alzheimer’s disease.

Jazz Pharmaceuticals plc has disclosed macrocyclic orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia, narcolepsy and sleep disorders.

NZP UK Ltd. has divulged 3-azasteroid compounds reported to be useful for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome, acute radiation syndrome and neurodegenerative disorders.

Researchers at Daegu-Gyeongbuk Medical Innovation Foundation and Korean Research Institute of Bioscience and Biotechnology have identified acetyl-CoA carboxylase (ACC) inhibitors reported to be useful for the treatment of liver cancer.

Synnovation Therapeutics Inc. has synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA-related overgrowth spectrum (PROS).

Researchers at Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College have disclosed pyrrolopyrimidine compounds acting as Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of chronic lymphocytic leukemia, lymphoma, primary central nervous system, non-Hodgkin lymphoma, and rheumatoid arthritis.

Innovstone Therapeutics Ltd. has synthesized aromatic heterocyclic compounds acting as leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease.